Albert Bourla, Pfizer CEO (Lintao Zhang/Getty Images)
October 13, 2023 05:35 PM EDTUpdated October 16, 10:22 AM
Pharma

Up­dat­ed: Pfiz­er plans $3.5B in cost cuts amid Covid slide, while Mod­er­na sticks by guid­ance

Drew Armstrong

Executive Editor

Pfiz­er will be­gin a com­pa­ny-wide cost-cut­ting pro­gram this year and next, part of a plan to bring the com­pa­ny’s costs in line with a world …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times